Please login to the form below
AZD3293
This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down
Latest news
-
Biogen rises on more positive data for Alzheimer's candidate
compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
-
Lilly taps AstraZeneca for another anti-amyloid drug
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
-
Lilly sinks as solanezumab fails again in Alzheimer's
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
-
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug
AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
-
Eisai and Biogen plan phase III trials for Alzheimer's drug
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- GSK hires Merck KGaA exec to lead US pharma business
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- Novartis chooses internal replacement for US pharma president role
- Cello Health acquires US consultancy ISS
- Empowered patients: shaking the foundations of healthcare
- Roche’s Hemlibra scores broader NHS funding
- AZ’s Imfinzi combo bombs again in non-small cell lung cancer
- NICE’s fast-track catapults Skyrizi into market
- GSK files anaemia drug daprodustat in Japan, its first market
PMHub
Apex.co.uk Conferences, Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
